0.40
+0.0145(+3.72%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.39 |
| Day High | 0.41 |
| Day Low | 0.39 |
| 52-Week High | 4.53 |
| 52-Week Low | 0.37 |
| Volume | 159,875 |
| Average Volume | 544,291 |
| Market Cap | 3.88M |
| PE | -0.1 |
| EPS | -4.22 |
| Moving Average 50 Days | 0.44 |
| Moving Average 200 Days | 0.98 |
| Change | 0.01 |
If you invested $1000 in Theriva Biologics, Inc. (TOVX) 10 years ago, it would be worth $0.02 as of September 08, 2025 at a share price of $0.405. Whereas If you bought $1000 worth of Theriva Biologics, Inc. (TOVX) shares 5 years ago, it would be worth $2.97 as of September 08, 2025 at a share price of $0.405.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday,
Theriva Biologics Announces Closing of $7.5 Million Public Offering
GlobeNewswire Inc.
May 08, 2025 8:30 PM GMT
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unme
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
GlobeNewswire Inc.
May 07, 2025 1:17 PM GMT
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unme